IHI Quote, Financials, Valuation and Earnings

iShares Biotechnology ETF has a net margin of -- compared to iShares US Medical Devices ETF's net margin of --. iShares US Medical Devices ETF's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.

iShares US Medical Devices ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares US Medical Devices ETF has higher upside potential than iShares Biotechnology ETF, analysts believe iShares US Medical Devices ETF is more attractive than iShares Biotechnology ETF.

iShares US Medical Devices ETF has a beta of 0.981, which suggesting that the stock is 1.854% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.216%.

iShares US Medical Devices ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.46%. iShares Biotechnology ETF offers a yield of 0.31% to investors and pays a quarterly dividend of $0.12 per share. iShares US Medical Devices ETF pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.

iShares US Medical Devices ETF quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. iShares US Medical Devices ETF's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, iShares US Medical Devices ETF's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares US Medical Devices ETF is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.

iShares US Healthcare ETF has a net margin of -- compared to iShares US Medical Devices ETF's net margin of --. iShares US Medical Devices ETF's return on equity of -- beat iShares US Healthcare ETF's return on equity of --.

iShares US Medical Devices ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares US Medical Devices ETF has higher upside potential than iShares US Healthcare ETF, analysts believe iShares US Medical Devices ETF is more attractive than iShares US Healthcare ETF.

iShares US Medical Devices ETF has a beta of 0.981, which suggesting that the stock is 1.854% less volatile than S&P 500. In comparison iShares US Healthcare ETF has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.652%.

iShares US Medical Devices ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.46%. iShares US Healthcare ETF offers a yield of 1.25% to investors and pays a quarterly dividend of $0.16 per share. iShares US Medical Devices ETF pays -- of its earnings as a dividend. iShares US Healthcare ETF pays out -- of its earnings as a dividend.

iShares US Medical Devices ETF quarterly revenues are --, which are smaller than iShares US Healthcare ETF quarterly revenues of --. iShares US Medical Devices ETF's net income of -- is lower than iShares US Healthcare ETF's net income of --. Notably, iShares US Medical Devices ETF's price-to-earnings ratio is -- while iShares US Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares US Medical Devices ETF is -- versus -- for iShares US Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.

Amplify Weight Loss Drug & Treatment ETF has a net margin of -- compared to iShares US Medical Devices ETF's net margin of --. iShares US Medical Devices ETF's return on equity of -- beat Amplify Weight Loss Drug & Treatment ETF's return on equity of --.

iShares US Medical Devices ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Amplify Weight Loss Drug & Treatment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares US Medical Devices ETF has higher upside potential than Amplify Weight Loss Drug & Treatment ETF, analysts believe iShares US Medical Devices ETF is more attractive than Amplify Weight Loss Drug & Treatment ETF.

iShares US Medical Devices ETF has a beta of 0.981, which suggesting that the stock is 1.854% less volatile than S&P 500. In comparison Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iShares US Medical Devices ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.46%. Amplify Weight Loss Drug & Treatment ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.22 per share. iShares US Medical Devices ETF pays -- of its earnings as a dividend. Amplify Weight Loss Drug & Treatment ETF pays out -- of its earnings as a dividend.

iShares US Medical Devices ETF quarterly revenues are --, which are smaller than Amplify Weight Loss Drug & Treatment ETF quarterly revenues of --. iShares US Medical Devices ETF's net income of -- is lower than Amplify Weight Loss Drug & Treatment ETF's net income of --. Notably, iShares US Medical Devices ETF's price-to-earnings ratio is -- while Amplify Weight Loss Drug & Treatment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares US Medical Devices ETF is -- versus -- for Amplify Weight Loss Drug & Treatment ETF. Usually stocks with elevated PS ratios are considered overvalued.

Vanguard Health Care Index Fund ETF has a net margin of -- compared to iShares US Medical Devices ETF's net margin of --. iShares US Medical Devices ETF's return on equity of -- beat Vanguard Health Care Index Fund ETF's return on equity of --.

iShares US Medical Devices ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Vanguard Health Care Index Fund ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares US Medical Devices ETF has higher upside potential than Vanguard Health Care Index Fund ETF, analysts believe iShares US Medical Devices ETF is more attractive than Vanguard Health Care Index Fund ETF.

iShares US Medical Devices ETF has a beta of 0.981, which suggesting that the stock is 1.854% less volatile than S&P 500. In comparison Vanguard Health Care Index Fund ETF has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.532%.

iShares US Medical Devices ETF has a quarterly dividend of $0.03 per share corresponding to a yield of 0.46%. Vanguard Health Care Index Fund ETF offers a yield of 1.59% to investors and pays a quarterly dividend of $0.94 per share. iShares US Medical Devices ETF pays -- of its earnings as a dividend. Vanguard Health Care Index Fund ETF pays out -- of its earnings as a dividend.

iShares US Medical Devices ETF quarterly revenues are --, which are smaller than Vanguard Health Care Index Fund ETF quarterly revenues of --. iShares US Medical Devices ETF's net income of -- is lower than Vanguard Health Care Index Fund ETF's net income of --. Notably, iShares US Medical Devices ETF's price-to-earnings ratio is -- while Vanguard Health Care Index Fund ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares US Medical Devices ETF is -- versus -- for Vanguard Health Care Index Fund ETF. Usually stocks with elevated PS ratios are considered overvalued.